Tonia Alexander

Tonia Alexander supports the National Institute of Allergy and Infectious Diseases (NIAID) in executing mission-critical procurement initiatives aligned with the agency’s mandate to combat infectious, immunologic, and allergic diseases. While her formal title is not publicly designated, her procurement activities center on acquiring advanced laboratory equipment, diagnostic reagents, and specialized biocontainment infrastructure essential for high-containment research and medical countermeasure development. She manages a diverse portfolio of acquisitions spanning technical services, manufacturing, and equipment maintenance, ensuring that NIAID’s research capabilities remain at the forefront of global public health preparedness. Alexander maintains consistent contracting relationships with key vendors including Quality Biological, Inc., a leading provider of biological reference materials, and Genomic Labs Ltd., which supports genomic sequencing and diagnostic assay development. Her procurement approach emphasizes technical precision and regulatory compliance, favoring partners with proven expertise in biosafety Level 3 and 4 environments, in-vitro diagnostic production, and analytical instrumentation. These partnerships are strategically cultivated to ensure continuity of supply for time-sensitive research and emergency response initiatives. Her contracting patterns reflect a strong preference for open competition, with 80% of awards issued without set-asides, yet she actively supports small business participation through 20% Total Small Business Set-Asides under FAR 19.5. This balanced approach ensures market competitiveness while fostering innovation from small, technically specialized firms. She does not prioritize socioeconomically targeted set-asides like 8(a) or HUBZone, instead focusing on capability-driven vendor selection. Alexander’s primary NAICS focus areas include Electronic and Precision Equipment Repair and Maintenance (30%), Analytical Laboratory Instrument Manufacturing (15%), and In-Vitro Diagnostic Substance Manufacturing (10%), underscoring her deep engagement with diagnostic technologies, biosafety systems, and laboratory automation. Her expertise lies in procuring high-complexity, regulated products and services that directly enable NIAID’s mission to accelerate biomedical responses to emerging threats.